Strategic partnerships Arctoris is actively expanding collaborations with top-tier academic and biotech institutions (e.g., University of Cambridge, Kings College London) and industry players (Intellomx). This suggests ongoing demand for AI-driven, automated drug discovery capabilities and an opportunity to position Ulysses as a preferred platform for co-development or sponsored research programs.

Cloud lab leadership Forbes recognition as a pioneer of cloud lab for cancer research indicates market credibility and growing interest in automated, data-rich biology workflows. Sales conversations can leverage this narrative to attract larger CROs and biotechs seeking scalable, reproducible experimentation and data analytics.

Acquired assets leverage The acquisition of Eli Lilly's Life Sciences Studio signals expanded automation capacity and a validated technology stack. This can be framed as an accelerated path to scale drug discovery programs, enabling faster target-to-candidate progression for partners with aggressive timelines.

Expansion momentum A significant laboratory expansion in Oxfordshire (9,000 sq ft) demonstrates growth readiness and capacity to onboard new clients. This readiness can be highlighted to prospective partners needing additional lab throughput or multi-project programs with disciplined data capture and reproducible outputs.

Data-driven value Emphasis on data quality, reproducibility, and a full-suite discovery ecosystem positions Arctoris as a turnkey, data-centric PRO. This offers a compelling upsell to customers seeking end-to-end automation, advanced analytics, and integrated consulting for assay design and clinic-ready progression.